Supplemental Digital Content 1. HIV-related Characteristics as of the First Pubertal Assessment* for 2086 Perinatally HIV-infected Children, by Sex

		Sex	
Characteristic	Total (N=2086)	Boys (N=1054)	Girls (N=1032)
CD4 T-lymphocyte percentage (CD4%)			
Median (IQR)	30 (22, 37)	28 (20, 36)	32 (24, 39)
0-<15%	257 (12%)	160 (15%)	97 (9%)
15-25%	462 (22%)	256 (25%)	206 (20%)
>25%	1,348 (65%)	628 (60%)	720 (70%)
Not available	19	10 (1%)	9 (1%)
Nadir CD4%, Median (IQR)	20 (12, 28)	19 (11, 26)	22 (14, 29)
HIV-1 Plasma RNA Concentration			
Median log HIV-1 RNA (IQR)	2.90 (2.60, 4.10)	3.04 (2.60, 4.27)	2.74 (2.60, 3.90)
0-400 copies/mL	699 (45%)	350 (43%)	349 (47%)
401-10,000 copies/mL	434 (28%)	206 (26%)	228 (31%)
>10,000 copies/mL	417 (27%)	250 (31%)	167 (22%)
Not available	536	248	288
Peak HIV-1Plasma RNA Concentration (copies/mL), Median (IQR)	N=1550, 28,536 (1,844, 161,881)	N=806, 37,170 (2,364, 170,000)	N=744, 22,617 (1,417, 141,346)
Log Copy-years Viremia; Median (IQR)	N=1079, 4.27 (3.38, 4.97)	N=548 4.40 (3.50, 4.94)	N=531 4.19 (3.29, 5.00)
CDC Class C Condition, N (%)	667 (32%)	341 (32%)	326 (32%)
ARV treatment at first pubertal assessment (n	ot mutually exclus	ive), N (%)	
On cART	1,334 (64%)	702 (67%)	632 (61%)
On PI-containing regimen	1,232 (59%)	646 (61%)	586 (57%)
On NNRTI-containing regimen	568 (27%)	311 (30%)	257 (25%)
Duration of prior treatment** (yrs), median (IQ	R)		
Years on cART, among prior users	N=1464, 3.24 (1.62, 5.20)	N=771, 3.16 (1.54, 4.93)	N=693, 3.27 (1.67, 5.45)
Years on any PI-containing regimen	N=1400, 3.12 (1.66, 4.99)	N=740, 3.00 (1.54, 4.74)	N=660, 3.24 (1.75, 5.12)
Years on any NNRTI-containing regimen	N=938, 1.65 (0.78, 3.06)	N=519, 1.51 (0.76, 3.01)	N=419, 1.77 (0.79, 3.10)

IQR = interquartile range; ARV = antiretroviral; cART = combination antiretroviral treatment (at least 3 drugs from at least 3 drug classes); PI = protease inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; CDC = Centers for Disease Control and Prevention

^{*}All HIV-disease related characteristics are based on measures available prior to or at the first pubertal assessment, at age 7 years or older. BMI and height Z-scores are sex- and age-adjusted Z-scores based on CDC 2000 growth standards using the latest BMI and height measured as of the first pubertal assessment.

** Duration of prior ARV summarized among the subset of youth with any prior use of regimen; each regimen is considered

separately and categories are not mutually exclusive.